The critical role of CD4+ T cells (54) in promoting robust, long-lived SARS-CoV-2-specific antibody levels and in response to mRNA vaccines has been shown, including in HCT and cellular therapy recipients, in whom COVID-19 vaccines are not precluded even when B-cell aplasia occurs (55). The gene discussed is CD4; the disease is COVID-19.